Profil
Shubh Goel worked as an Executive Director-Global Early Commercialization at Celgene Corp.
from 2013 to 2017.
Prior to that, he was the Head-Global Launch Team at Bayer AG from 2007 to 2011.
He also worked as the Vice President-Marketing at AVEO Pharmaceuticals, Inc. from 2011 to 2013.
Recently, he served as the Chief Commercial Officer at Fennec Pharmaceuticals, Inc. from 2019 to 2022.
Additionally, he held the position of Vice President-Commercial Strategy & Operations at Odonate, Inc. Mr. Goel completed his undergraduate degree from the University of Bath.
Anciens postes connus de Shubh Goel
| Sociétés | Poste | Fin |
|---|---|---|
| FENNEC PHARMACEUTICALS INC. | Corporate Officer/Principal | 28/02/2022 |
| CELGENE | Corporate Officer/Principal | 01/01/2017 |
| AVEO PHARMACEUTICALS, INC. | Sales & Marketing | 01/01/2013 |
| BAYER AG | Corporate Officer/Principal | 01/01/2011 |
| ODONATE, INC. | Chief Operating Officer | 19/11/2018 |
Formation de Shubh Goel
| University of Bath | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BAYER AG | Health Technology |
| FENNEC PHARMACEUTICALS INC. | Health Technology |
| ODONATE, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
